This is to inform that due to some circumstances beyond the organizer control, "3rd Edition of International Precision Medicine Conference" (IPMC 2023) scheduled during April 24-26, 2023 in Orlando, Florida, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at precision-medicine@magnusconference.com or call + 1 (702) 988 2320.
Companion diagnostic tests identify specific genetic mutations and biomarkers in individuals who are most likely to benefit from precision medicine treatment, lowering the number of patients who are treated. Companion diagnostics play a pivotal role in the development of targeted medications, and their effectiveness determines the success of this type of therapy to a great extent. Companion diagnostic assays use a single patient as a reference point and will be crucial in the transition to more precise and personalized medication. These are medical gadgets that assist doctors in determining the treatments and dosages to offer patients, based on the patient's individual needs. The companion diagnostic is necessary for the drug's safe and effective use.
Title : Copper (II) complexes as potential anticancer agents
Salah S Massoud, University of Louisiana, United States
Title : Leveraging blockchain technology, edge computing and federated learning to enhance outcomes in precision medicine
Ingrid Vasiliu Feltes, MEDNAX, United States
Title : The new horizons in the patient- centered care for understanding of the reasons of its health problems – Psychosynthesis approach
Ewa Danuta Bialek, Institute of Psychosynthesis, Poland
Title : Hegazy theory for interpretation of human parthenogenesis: A new hypothesis
Abdelmonem Awad Hegazy, Zagazig University, Egypt
Title : Precision Oncology and Personalised Medicine: Innovative Technology for the Treatment of Colorectal Cancer
Huiqin Yang, ICON Clinical Research Ltd, United Kingdom
Title : The role of CD44v6 as a new immunotherapy target for urothelial cancer
Iris Adriana Maria Lodewijk, Institute of Biomedical Research, Spain